Biogen Inc. $BIIB Stock Holdings Lowered by Savant Capital LLC

Savant Capital LLC lowered its position in shares of Biogen Inc. (NASDAQ:BIIB) by 82.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,568 shares of the biotechnology company’s stock after selling 17,081 shares during the period. Savant Capital LLC’s holdings in Biogen were worth $628,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. WPG Advisers LLC raised its stake in shares of Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC raised its stake in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares in the last quarter. First Horizon Corp bought a new stake in shares of Biogen during the fourth quarter valued at about $30,000. WFA of San Diego LLC bought a new stake in shares of Biogen during the second quarter valued at about $32,000. Finally, GoalVest Advisory LLC bought a new stake in shares of Biogen during the fourth quarter valued at about $35,000. Institutional investors own 87.93% of the company’s stock.

Biogen Trading Up 3.8%

Shares of BIIB opened at $195.96 on Thursday. The business’s 50-day moving average price is $187.23 and its 200 day moving average price is $183.04. The stock has a market capitalization of $28.93 billion, a P/E ratio of 21.03, a P/E/G ratio of 1.66 and a beta of 0.20. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts expect that Biogen Inc. will post 14.18 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BIIB shares. TD Cowen lifted their price objective on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Truist Financial dropped their price target on shares of Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a research report on Monday, April 13th. Oppenheimer boosted their price target on shares of Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Wolfe Research set a $231.00 price target on shares of Biogen in a research report on Monday, February 9th. Finally, BMO Capital Markets boosted their price target on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $215.81.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.